Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 1
Terminated
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Genuv Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04326283
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath